Literature DB >> 34913005

Renal denervation therapy for hypertension: truths and half-truths: Renal denervation therapy for hypertension.

C Venkata Ram1, S S Iyengar2, Gurpreet Wander3, Tiny Nair4, A Sreenivas Kumar1, Saumitra Ray5, Satyavan Sharma6.   

Abstract

Systemic hypertension is a major contributing factor for excessive morbidity and mortality globally. Experimental studies and early clinical trials showed excellent therapeutic responses to renal denervation (RDN) in patients with hypertension. However meta-analyses and objective assessments have failed to show that RDN therapy has any significant effect on blood pressure.  The aim of this review is to introduce the different methods that can be used in RDN, along with the benefits and disadvantages of these methods. Radiofrequency (RF) ablation (of renal nerves) is the most com-mon method of RDN, and we discuss the clinical evaluation of this method in the SYMPLICITY RDN trials. Finally, the development of second-generation RF devices and more comprehensive RDN procedures lead us to consider the current status and future path for RDN.

Entities:  

Year:  2021        PMID: 34913005      PMCID: PMC8657029          DOI: 10.4244/AIJ-D-21-00013

Source DB:  PubMed          Journal:  AsiaIntervention        ISSN: 2426-3958


  9 in total

1.  Renal Denervation in High-Risk Patients With Hypertension.

Authors:  Felix Mahfoud; Giuseppe Mancia; Roland Schmieder; Krzysztof Narkiewicz; Luis Ruilope; Markus Schlaich; Robert Whitbourn; Andreas Zirlik; Thomas Zeller; Philipp Stawowy; Sidney A Cohen; Martin Fahy; Michael Böhm
Journal:  J Am Coll Cardiol       Date:  2020-06-16       Impact factor: 24.094

2.  Status of Renal Denervation Therapy for Hypertension.

Authors:  C Venkata S Ram
Journal:  Circulation       Date:  2019-01-29       Impact factor: 29.690

Review 3.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright
Journal:  J Am Coll Cardiol       Date:  2017-11-13       Impact factor: 24.094

4.  Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial.

Authors:  Michel Azizi; Roland E Schmieder; Felix Mahfoud; Michael A Weber; Joost Daemen; Justin Davies; Jan Basile; Ajay J Kirtane; Yale Wang; Melvin D Lobo; Manish Saxena; Lida Feyz; Florian Rader; Philipp Lurz; Jeremy Sayer; Marc Sapoval; Terry Levy; Kintur Sanghvi; Josephine Abraham; Andrew S P Sharp; Naomi D L Fisher; Michael J Bloch; Helen Reeve-Stoffer; Leslie Coleman; Christopher Mullin; Laura Mauri
Journal:  Lancet       Date:  2018-05-23       Impact factor: 79.321

5.  Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study.

Authors:  Henry Krum; Markus P Schlaich; Paul A Sobotka; Michael Böhm; Felix Mahfoud; Krishna Rocha-Singh; Richard Katholi; Murray D Esler
Journal:  Lancet       Date:  2013-11-07       Impact factor: 79.321

6.  Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial.

Authors:  Murray D Esler; Michael Böhm; Horst Sievert; Christian L Rump; Roland E Schmieder; Henry Krum; Felix Mahfoud; Markus P Schlaich
Journal:  Eur Heart J       Date:  2014-06-04       Impact factor: 29.983

7.  Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial.

Authors:  David E Kandzari; Michael Böhm; Felix Mahfoud; Raymond R Townsend; Michael A Weber; Stuart Pocock; Konstantinos Tsioufis; Dimitrios Tousoulis; James W Choi; Cara East; Sandeep Brar; Sidney A Cohen; Martin Fahy; Garrett Pilcher; Kazuomi Kario
Journal:  Lancet       Date:  2018-05-23       Impact factor: 79.321

8.  A controlled trial of renal denervation for resistant hypertension.

Authors:  Deepak L Bhatt; David E Kandzari; William W O'Neill; Ralph D'Agostino; John M Flack; Barry T Katzen; Martin B Leon; Minglei Liu; Laura Mauri; Manuela Negoita; Sidney A Cohen; Suzanne Oparil; Krishna Rocha-Singh; Raymond R Townsend; George L Bakris
Journal:  N Engl J Med       Date:  2014-03-29       Impact factor: 91.245

9.  Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial.

Authors:  Raymond R Townsend; Felix Mahfoud; David E Kandzari; Kazuomi Kario; Stuart Pocock; Michael A Weber; Sebastian Ewen; Konstantinos Tsioufis; Dimitrios Tousoulis; Andrew S P Sharp; Anthony F Watkinson; Roland E Schmieder; Axel Schmid; James W Choi; Cara East; Anthony Walton; Ingrid Hopper; Debbie L Cohen; Robert Wilensky; David P Lee; Adrian Ma; Chandan M Devireddy; Janice P Lea; Philipp C Lurz; Karl Fengler; Justin Davies; Neil Chapman; Sidney A Cohen; Vanessa DeBruin; Martin Fahy; Denise E Jones; Martin Rothman; Michael Böhm
Journal:  Lancet       Date:  2017-08-28       Impact factor: 79.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.